Trials / Completed
CompletedNCT00800332
Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy
Double-blind, Placebo-controlled Dose-finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Cytos Biotechnology AG · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve allergy symptoms in patients with house dust mite allergy. The active treatment will be compared against placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CYT003-QbG10 | subcutaneous injection |
| DRUG | Placebo | subcutaneous injection |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-04-01
- Completion
- 2010-11-01
- First posted
- 2008-12-02
- Last updated
- 2010-11-15
Locations
8 sites across 6 countries: Estonia, Germany, Greece, Latvia, Lithuania, Romania
Source: ClinicalTrials.gov record NCT00800332. Inclusion in this directory is not an endorsement.